Federal Register / Vol. 69, No. 204 / Friday, October 22, 2004 / Notices 62051

review and comment were published in 

the Federal Register on October 23, 

2001, and August 7, 2001, with notice 

of a 90-day public comment period for 

each profile, starting from the actual 

release date. Following the close of the 

comment period, chemical-specific 

comments were addressed, and, where 

appropriate, changes were incorporated 

into each profile. The public comments 

and other data submitted in response to 

the Federal Register notices bear the 

docket control number ATSDR–174 and 

ATSDR–171. This material is available 

for public inspection at the Division of 

Toxicology, Agency for Toxic 

Substances and Disease Registry, 1825 

Century Boulevard, Atlanta, Georgia, 

(not a mailing address) between 8 a.m. 

and 4:30 p.m., Monday through Friday, 

except legal holidays. 

Availability 

This notice announces the availability 

of one update and four new final 

toxicological profiles, comprising the 

2nd set developed for the Department of 

Energy, prepared by ATSDR. The 

following toxicological profiles are now 

available through the U.S. Department 

of Commerce, National Technical 

Information Service (NTIS), 5285 Port 

Royal Road, Springfield, Virginia 22161, 

telephone 1–800–553–6847. There is a 

charge for these profiles as determined 

by NTIS.

SECOND SET OF DOE PROFILES

Toxicological profile NTIS order No. CAS No. 

1. Americium ...................................................................................................................................................... PB2004–104396 7440–35–9 

2. Cesium ........................................................................................................................................................... PB2004–104397 7440–46–2 

3. Cobalt (Update) ............................................................................................................................................. PB2004–104398 7440–48–4 

4. Iodine ............................................................................................................................................................. PB2004–104399 7553–56–2 

5. Strontium ....................................................................................................................................................... PB2004–104400 7440–35–9 

Georgi Jones, 

Director, Office of Policy, Planning, and 

Evaluation, National Center for 

Environmental Health/Agency for Toxic 

Substances and Disease Registry.

[FR Doc. 04–23617 Filed 10–21–04; 8:45 am] 

BILLING CODE 4163–70–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Cooperative Agreement for the 

Surveillance, and Prevention of Birth 

Defects 

Announcement Type: New. 

Funding Opportunity Number: RFA 

05006. 

Catalog of Federal Domestic 

Assistance Number: 93.283. 

Application Deadline: December 21, 

2004. 

I. Funding Opportunity Description 

Authority: This program is authorized 

under sections 317(k)(2) of the Public 

Health Service Act [42 U.S.C. 

247b(k)(2)]. 

Purpose: The purpose of the program 

is to promote international surveillance 

and prevention of birth defects. This 

program addresses the ‘‘Healthy People 

2010’’ focus area(s) of Maternal, Infant 

and Child Health. 

Measurable outcomes of the program 

will be in alignment with one of the 

following performance goal(s) for the 

National Center on Birth Defects and 

Developmental Disabilities (NCBDDD): 

(1) Prevent birth defects and 

developmental disabilities (2) improve 

the health and quality of life of 

Americans with disabilities. 

This announcement is only for nonresearch activities supported by CDC. If 

research is proposed, the application 

will not be reviewed. For the definition 

of research, please see the CDC web site 

at the following Internet address: http:/

/www.cdc.gov/od/ads/opspoll1.htm

Activities: Awardee activities for this 

program are as follows: 

• Develop and/or maintain an 

international birth defects database that 

includes data from developed and 

developing countries from different 

areas of the world. 

• Promote and operate an 

international collaboration and data 

clearinghouse among international 

partners and birth defect registries that 

enables international collaborative birth 

defect surveillance, epidemiologic 

assessment, and capacity building. 

• Using such international partners 

and the international birth defects 

database, evaluate, compare and 

confirm patterns and trends of birth 

defects occurrences. 

• Obtain, compile, and publish birth 

defect surveillance data from areas in 

the developed and developing world to 

assess the impact of birth defects. 

• In collaboration with international 

partners, conduct secondary data 

analyses in order to evaluate potential 

birth defect risk factors and identify 

areas in need of epidemiologic 

assessments. 

• Disseminate the birth defect 

surveillance data to member programs, 

partners such as national and 

international organizations, the World 

Health Organization, other health 

agencies, and other interested parties. 

• Evaluate the changes in the 

occurrence of selected adverse 

reproductive outcomes likely to be 

prevented by folic acid (e.g., neural tube 

defects, oral clefts, and certain heart 

defects) in relation to folic acid policies 

that have been instituted in different 

areas of the world, including the 

Americas, Europe, the Middle East, 

Asia, and Africa.

• Promote or develop tools and 

guidelines to assist the development of 

birth defects surveillance activities in 

both developed and developing 

countries. 

In a cooperative agreement, CDC staff 

is substantially involved in the program 

activities, above and beyond routine 

grant monitoring. 

CDC Activities for this program are as 

follows: 

• Assist, if requested, in designing, 

developing, and evaluating 

methodologies and approaches used for 

population-based birth defects 

surveillance. 

• Assist, if requested, in analyzing 

surveillance data related to birth 

defects. 

• Assist, if requested, in providing 

scientific consultation and assistance in 

the study of birth defects and in the 

approaches to study design, 

methodology, and implementation in 

the conduct of secondary data analyses. 

• Assist, if requested, in the 

definition and format of the birth defect 

surveillance reports. 

• Assist, if requested in developing 

tools and guidelines for birth defect 

surveillance. 

II. Award Information 

Type of Award: Cooperative 

Agreement. CDC involvement in this 

62052 Federal Register / Vol. 69, No. 204 / Friday, October 22, 2004 / Notices 

program is listed in the Activities 

Section above. 

Fiscal Year Funds: 2005. 

Approximate Total Funding: $150,000 

(This amount is an estimate, and is 

subject to availability of funds.) 

Approximate Number of Awards:

One. 

Approximate Average Award:

$150,000 (This amount is for the first

12-month budget period.). 

Floor of Award Range: None. 

Ceiling of Award Range: None. 

Anticipated Award Date: April 1, 

2005. 

Budget Period Length: 12-months. 

Project Period Length: Up to three 

years. 

Throughout the project period, CDC’s 

commitment to continuation of awards 

will be conditioned on the availability 

of funds, evidence of satisfactory 

progress by the recipient (as 

documented in required reports), and 

the determination that continued 

funding is in the best interest of the 

Federal Government. 

III. Eligibility Information 

III.1. Eligible Applicants 

• Applications may be submitted by 

private nonprofit organizations. 

III.2. Cost Sharing or Matching 

Matching funds are not required for 

this program. 

III.3. Other 

CDC will accept and review 

applications with budgets greater than 

the ceiling of the award range. 

Special Requirements: If your 

application is incomplete or nonresponsive to the special requirements 

listed in this section, it will not be 

entered into the review process. You 

will be notified that your application 

did not meet submission requirements. 

• Late applications will be considered 

non-responsive. See section ‘‘IV.3. 

Submission Dates and Times’’ for more 

information on deadlines. 

• Note: Title 2 of the United States 

Code Section 1611 states that an 

organization described in Section 

501(c)(4) of the Internal Revenue Code 

that engages in lobbying activities is not 

eligible to receive Federal funds 

constituting an award, grant, or loan.

IV. Application and Submission 

Information 

IV.1. Address To Request Application 

Package 

To apply for this funding opportunity 

use application form PHS 5161. 

Application forms and instructions are 

available on the CDC web site, at the 

following Internet address: 

www.cdc.gov/od/pgo/forminfo.htm.

If you do not have access to the 

Internet, or if you have difficulty 

accessing the forms on-line, you may 

contact the CDC Procurement and 

Grants Office Technical Information 

Management Section (PGO–TIM) staff 

at: 770–488–2700. Application forms 

can be mailed to you. 

IV.2. Content and Form of Submission 

Application: You must submit a 

project narrative with your application 

forms. The narrative must be submitted 

in the following format: 

• Maximum number of pages: 25 if 

your narrative exceeds the page limit, 

only the first pages which are within the 

page limit will be reviewed. 

• Font size: 12 point unreduced. 

• Double spaced. 

• Paper size: 8.5 by 11 inches. 

• Page margin size: One inch. 

• Printed only on one side of page. 

• Held together only by rubber bands 

or metal clips; not bound in any other 

way. 

Your narrative should address 

activities to be conducted over the 

entire project period, and must include 

the following items in the order listed: 

• Objectives. 

• Methods. 

• Evaluation. 

• Organizational and Program 

Personnel Capability. 

• Program Plan. 

• Budget and Justification (Not 

included in page limitation). 

Additional information may be 

included in the application appendices. 

The appendices will not be counted 

toward the narrative page limit. This 

additional information includes: 

Curriculum Vitaes. 

Organizational Charts. 

Letters of Support. 

You are required to have a Dun and 

Bradstreet Data Universal Numbering 

System (DUNS) number to apply for a 

grant or cooperative agreement from the 

Federal government. The DUNS number 

is a nine-digit identification number, 

which uniquely identifies business 

entities. Obtaining a DUNS number is 

easy and there is no charge. To obtain 

a DUNS number, access 

www.dunandbradstreet.com or call 1–

866–705–5711. 

For more information, see the CDC 

web site at: http://www.cdc.gov/od/pgo/

funding/pubcommt.htm. If your 

application form does not have a DUNS 

number field, please write your DUNS 

number at the top of the first page of 

your application, and/or include your 

DUNS number in your application cover 

letter. 

Additional requirements that may 

require you to submit additional 

documentation with your application 

are listed in section ‘‘VI.2. 

Administrative and National Policy 

Requirements.’’

IV.3. Submission Dates and Times 

Application Deadline Date: December 

21, 2004.

Explanation of Deadlines:

Applications must be received in the 

CDC Procurement and Grants Office by 

4 p.m. Eastern Time on the deadline 

date. If you submit your application by 

the United States Postal Service or 

commercial delivery service, you must 

ensure that the carrier will be able to 

guarantee delivery by the closing date 

and time. If CDC receives your 

submission after closing due to: (1) 

Carrier error, when the carrier accepted 

the package with a guarantee for 

delivery by the closing date and time, or 

(2) significant weather delays or natural 

disasters, you will be given the 

opportunity to submit documentation of 

the carriers guarantee. If the 

documentation verifies a carrier 

problem, CDC will consider the 

submission as having been received by 

the deadline. 

This announcement is the definitive 

guide on LOI and application content, 

submission address, and deadline. It 

supersedes information provided in the 

application instructions. If your 

submission does not meet the deadline 

above, it will not be eligible for review, 

and will be discarded. You will be 

notified that you did not meet the 

submission requirements. 

CDC will not notify you upon receipt 

of your submission. If you have a 

question about the receipt of your LOI 

or application, first contact your courier. 

If you still have a question, contact the 

PGO–TIM staff at: 770–488–2700. Before 

calling, please wait two to three days 

after the submission deadline. This will 

allow time for submissions to be 

processed and logged. 

IV.4. Intergovernmental Review of 

Applications 

Executive Order 12372 does not apply 

to this program. 

IV.5. Funding restrictions 

Restrictions as found in 45 CFR Parts 

74 and 92 and OMB Circular 1–122, 

which must be taken into account while 

writing your budget, are as follows: 

• Funds may not be used for research. 

• Reimbursement of pre-award costs 

is not allowed. 

• Funds may be spent for reasonable 

program purposes, including personnel, 

travel, supplies, and services. 

Federal Register / Vol. 69, No. 204 / Friday, October 22, 2004 / Notices 62053

Equipment may be purchased if deemed 

necessary to accomplish program 

objectives, however, prior approval by 

CDC officials must be requested in 

writing. 

• The costs that are generally 

allowable in grants to domestic 

organizations are allowable to foreign 

institutions and international 

organizations, with the following 

exception: With the exception of the 

American University, Beirut and the 

World Health Organization, Indirect 

Costs will not be paid (either directly or 

through sub-award) to organizations 

located outside the territorial limits of 

the United States or to international 

organizations regardless of their 

location. 

• The applicant may contract with 

other organizations under this program; 

however the applicant must perform a 

substantial portion of the activities 

(including program management and 

operations, and delivery of prevention 

services for which funds are required.) 

• All requests for funds contained in 

the budget, shall be stated in U.S. 

dollars. Once an award is made, CDC 

will not compensate foreign grantees for 

currency exchange fluctuations through 

the issuance of supplemental awards. 

• You must obtain annual audit of 

these CDC funds (program-specific 

audit) by a U.S.-based audit firm with 

international branches and current 

licensure/authority in-country, and in 

accordance with International 

Accounting Standards or equivalent 

standard(s) approved in writing by CDC.

• A fiscal Recipient Capability 

Assessment may be required, prior to or 

post award, in order to review the 

applicant’s business management and 

fiscal capabilities regarding the 

handling of U.S. Federal funds. 

Guidance for completing your budget 

can be found on the CDC Web site, at 

the following Internet address: http://

www.cdc.gov/od/pgo/funding/

budgetguide.htm. 

IV.6. Other Submission Requirements 

Application Submission Address: 

Submit the original and two hard copies 

of your application by mail or express 

delivery service to: Technical 

Information Management—RFA#05006, 

CDC Procurement and Grants Office, 

2920 Brandywine Road, Atlanta, GA 

30341. 

Applications may not be submitted 

electronically at this time. 

V. Application Review Information 

V.1. Criteria 

Applicants are required to provide 

measures of effectiveness that will 

demonstrate the accomplishment of the 

various identified objectives of the 

cooperative agreement. Measures of 

effectiveness must relate to the 

performance goals stated in the 

‘‘Purpose’’ section of this 

announcement. Measures must be 

objective and quantitative, and must 

measure the intended outcome. These 

measures of effectiveness must be 

submitted with the application and will 

be an element of evaluation. 

Your application will be evaluated 

against the following criteria: 

1. Objectives (30 Points) 

Are the proposed objectives specific, 

measurable, and time-phased? 

2. Methods (30 Points) 

Are the proposed methods feasible? 

To what extent are the proposed 

methods likely to lead to the 

accomplishment of the proposed 

objectives? 

3. Evaluation (15 Points) 

Does the evaluation plan enable the 

applicant to determine the success of its 

activities and the benefits provided? 

4. Personnel (15 Points) 

Do the staff members have the 

experience, skills, and ability to develop 

and improve birth defects surveillance 

data to develop prevention programs 

and improve access to health services or 

early intervention programs? Are the 

staff roles clearly defined? 

5. Project Plan (10 Points) 

Is the plan adequate to carry out the 

proposed objectives? Does the applicant 

have a clear, concise understanding of 

the program requirements, objectives 

and purpose of the cooperative 

agreement? 

Also, does the applicant meet the CDC 

Policy requirements regarding the 

inclusion of women, ethnic, and racial 

groups in the proposed research? 

This includes: 

a. The proposed plan for the inclusion 

of both sexes and racial and ethnic 

minority populations for appropriate 

representation. 

b. The proposed justification when 

representation is limited or absent.

c. A statement as to whether the 

design of the study is adequate to 

measure differences when warranted. 

d. A statement as to whether the plans 

for recruitment and outreach for study 

participants include the process of 

establishing partnerships with 

community(ies) and recognition of 

mutual benefits. 

6. Budget and Justification (Reviewed, 

But Not Scored) 

V.2. Review and Selection Process 

Applications will be reviewed for 

completeness by the Procurement and 

Grants Office (PGO) staff, and for 

responsiveness by NCBDDD. Incomplete 

applications and applications that are 

non-responsive to the eligibility criteria 

will not advance through the review 

process. Applicants will be notified that 

their application did not meet 

submission requirements. 

An objective review panel will 

evaluate complete and responsive 

applications according to the criteria 

listed in the ‘‘V.1. Criteria’’ section 

above. 

Applications will be funded in order 

by score and rank determined by the 

review panel. 

CDC will provide justification for any 

decision to fund out of rank order. 

V.3. Anticipated Announcement and 

Award Dates 

April 1, 2005. 

VI. Award Administration Information 

VI.1. Award Notices 

Successful applicants will receive a 

Notice of Grant Award (NGA) from the 

CDC Procurement and Grants Office. 

The NGA shall be the only binding, 

authorizing document between the 

recipient and CDC. The NGA will be 

signed by an authorized Grants 

Management Officer, and mailed to the 

recipient fiscal officer identified in the 

application. 

Unsuccessful applicants will receive 

notification of the results of the 

application review by mail. 

VI.2. Administrative and National 

Policy Requirements 

45 CFR Parts 74 and 92.

For more information on the Code of 

Federal Regulations, see the National 

Archives and Records Administration at 

the following Internet address: http://

www.access.gpo.gov/nara/cfr/cfr-tablesearch.html.

The following additional 

requirements apply to this project: 

• AR–10 Smoke-Free Workplace 

Requirements. 

• AR–11 Healthy People 2010. 

• AR–12 Lobbying Restrictions. 

• AR–14 Accounting System 

Requirements. 

• AR–15 Proof of Non-Profit Status. 

• AR–25 Release and Sharing of 

Data. 

Additional information on these 

requirements can be found on the CDC 

web site at the following Internet 

62054 Federal Register / Vol. 69, No. 204 / Friday, October 22, 2004 / Notices 

address: http://www.cdc.gov/od/pgo/

funding/ARs.htm.

VI.3. Reporting Requirements 

You must provide CDC with an 

original, plus two hard copies of the 

following reports: 

1. Interim progress report, due no less 

than 90 days before the end of the 

budget period. The progress report will 

serve as your non-competing 

continuation application, and must 

contain the following elements: 

a. Current Budget Period Activities 

Objectives. 

b. Current Budget Period Financial 

Progress. 

c. New Budget Period Program 

Proposed Activity Objectives. 

d. Budget. 

e. Measures of Effectiveness. 

f. Additional Requested Information. 

2. Financial status report and annual 

progress report, no more than 90 days 

after the end of the budget period. 

3. Final financial and performance 

reports, no more than 90 days after the 

end of the project period. 

These reports must be mailed to the 

Grants Management or Contract 

Specialist listed in the ‘‘Agency 

Contacts’’ section of this announcement. 

VII. Agency Contacts 

We encourage inquiries concerning 

this announcement. For general 

questions, contact: Technical 

Information Management Section, CDC 

Procurement and Grants Office, 2920 

Brandywine Road, Atlanta, GA 30341, 

Telephone: (770) 488–2700. 

For program technical assistance, 

contact: J. David Erickson, Project 

Officer, CDC, NCBDDD, 1600 Clifton 

Road, NE (E86), Atlanta, GA 30333, 

Telephone: (404) 498–3825, E-mail: 

DErickson@cdc.gov.

For financial, grants management, or 

budget assistance, contact: Steward 

Nichols, Contract Specialist, CDC 

Procurement and Grants Office, 2920 

Brandywine Road, Atlanta, GA 30341, 

Telephone: (770) 488–2788, E-mail: 

SNichols@cdc.gov.

VIII. Other Information 

This and other CDC funding 

opportunity announcements can be 

found on the CDC web site, Internet 

address: http://www.cdc.gov. Click on 

‘‘Funding’’ then ‘‘Grants and 

Cooperative Agreements.’’

Information on the National Center on 

Birth Defects and Developmental 

Disabilities may be found on http://

www.cdc.gov. Click on ‘‘Birth Defects.’’

Dated: October 18, 2004. 

William P. Nichols, 

Acting Director, Procurement and Grants 

Office, Centers for Disease Control and 

Prevention.

[FR Doc. 04–23726 Filed 10–21–04; 8:45 am] 

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

CDC/HRSA Advisory Committee on 

HIV and STD Prevention and 

Treatment. 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) and the 

Health Resources and Services 

Administration (HRSA) announce the 

following committee meeting.

Name: CDC/HRSA Advisory Committee on 

HIV and STD Prevention and Treatment. 

Times and Dates: 8 a.m.–5 p.m., November 

18, 2004. 8 a.m.–12 p.m., November 19, 2004. 

Place: Doubletree Hotel Rockville, 1740 

Rockville Pike, Rockville, Maryland. 

Status: Open to the public, limited only by 

the space available. The meeting room will 

accommodate approximately 100 people. 

Purpose: This committee is charged with 

advising the Secretary, the Director, CDC and 

the Administrator, HRSA, regarding activities 

related to prevention and control of HIV/

AIDS and other STDs, the support of health 

care services to persons living with HIV/

AIDS, and education of health professionals 

and the public about HIV/AIDS and other 

STDs. 

Matters To Be Discussed: Agenda items 

include issues pertaining to (1) AIDS Drug 

Assistance Program (ADAP), (2) Ryan White 

Reauthorization, and (3) Impact of Crystal 

Methamphetamine on STD rates and HIV. 

Agenda items are subject to change as 

priorities dictate. 

For Further Information Contact:

Paulette Ford-Knights, Public Health 

Analyst, National Center for HIV, STD, and 

TB Prevention, 1600 Clifton Road, NE., 

Mailstop E–07, Atlanta, Georgia 30333. 

Telephone 404/639–8008, fax 404/639–3125, 

e-mail pbf7@cdc.gov.

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register Notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry.

Dated: October 18, 2004. 

Alvin Hall, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention.

[FR Doc. 04–23723 Filed 10–21–04; 8:45 am] 

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

National Center for Environmental 

Health/Agency for Toxic Substances 

and Disease Registry 

The Community and Tribal 

Subcommittee of the Board of Scientific 

Counselors (BSC), Centers for Disease 

Control and Prevention (CDC), National 

Center for Environmental Health 

(NCEH)/Agency for Toxic Substances 

and Disease Registry (ATSDR): 

Teleconference. 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), NCEH/ATSDR 

announces the following subcommittee 

meeting:

Name: Community and Tribal 

Subcommittee (CTS). 

Time and Date: 3 p.m.–4:30 p.m., 

November 2, 2004. 

Place: The teleconference will originate at 

the National Center for Environmental 

Health/Agency for Toxic Substances and 

Disease Registry in Atlanta, Georgia. Please 

see SUPPLEMENTARY INFORMATION for details 

on accessing the teleconference. 

Status: Open to the public, teleconference 

access limited only by availability of 

telephone ports. 

Purpose: Under the charge of the BSC, 

NCEH/ATSDR, the Community and Tribal 

Subcommittee will provide the board with a 

forum for community and tribal first-hand 

perspectives on the interactions and impacts 

of the NCEH/ATSDR’s national and regional 

policies, practices and programs. 

Matters To Be Discussed: The agenda will 

include a discussion on defining the new 

working relationship between the CTS and 

the board; a discussion on the development 

of a statement-of-work, to include topics that 

can be accomplished under the new charge, 

to be presented to the board; and a review of 

the task forces to the previous CTS. 

Agenda items are subject to change.

SUPPLEMENTARY INFORMATION: This 

conference call is scheduled to begin at 

3 p.m. eastern standard time. To 

participate in the teleconference, please 

dial 1 (877) 315–6535 and enter 

conference code 383520.

FOR FURTHER INFORMATION CONTACT:

Sandra Malcom, Committee 

Management Specialist, Office of 

Science, NCEH/ATSDR, M/S E–28, 1600 

Clifton Road, NE., Atlanta, Georgia 

30333, telephone 404/498–0003. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register

notices pertaining to announcements of 

meetings and other committee 

management activities, for both CDC/

ATSDR.